Suzhou Manufacturing Site

Our current facility in Suzhou of more than 460,000 sq ft is a small molecule manufacturing base for drug candidates and medicines, with an annual production capacity of about 300 million tablets and capsules and a biologics clinical development production facility of 2 x 500 liters capacity.

To accommodate our growing commercial and clinical demands, we have broken ground on a new small molecule manufacturing facility in Suzhou that will have the capability to produce up to 600 million solid oral dosages annually. This approximately 50,000 square meter state-of-the-art facility will be our small molecule campus, replacing the current Suzhou site in supporting our growing pipeline of small molecule medicines and drug candidates.